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A report on the Genetics Society autumn meeting ‘The
mouse: genetics and genome’, The Royal Society, London,
UK, 14 November 2003.
Functional annotation of the mouse genome was the theme
of the meeting and this is clearly a lofty goal. The mouse is a
unique model organism for understanding mammalian
biology owing to the availability of classical genetic
approaches as well as sequence-based manipulation
methods. The impressive group of mouse experimentalists
gathered for the day exemplified many of the clever tactics
being used in the mouse for functional dissection of a variety
of biological systems. Highlights are covered here. 
Tagging and tinkering with the mouse genome 
Allan Bradley (The Wellcome Trust Sanger Institute, Hinxton,
UK) estimated that only 15% of the mouse genome has been
functionally assessed via gene-targeting strategies, and he pre-
sented approaches to increase that percentage using
sequence-driven methods. He highlighted the usefulness of
embryonic stem (ES) cell libraries generated by genome-wide
gene-trapping strategies. The availability of the mouse
genome sequence means that determining the exact genomic
position of the insertions in these libraries is extremely rapid.
The average distance between insertions is 25 kilobases, and
13,000 of the insertion lines are predicted to be null muta-
tions. Notably, the targeting vector used to make the inser-
tions includes a site-specific recombination site, LoxP, which
facilitates systematic chromosome-engineering experiments.
The dizzying collection of engineered chromosome segments
generated by Bradley includes balancers, duplications and
deletions, suggesting that it will soon be as easy to perform
mutant phenotype screens in mice as it is in flies.
Another exciting reagent in Bradley’s quiver is the Bloom
syndrome mutant cell line (Blm-/-): a Blm-/- ES cell line has a
high level of mitotic recombination, which results in a
20-fold increase in the rate of loss of heterozygosity (LOH).
Unlike other cell lines with increased rates of LOH, such as
p53 mutant cells, the Blm-/- strain is genetically stable
(except for the aforementioned phenotype). By introducing
gene-trapping vectors into the Blm-/- cell line, Bradley’s
group has been able to identify recessive mutations in DNA
mismatch repair genes: the gene-trap event induces a muta-
tion, and the high rate of LOH generates the ‘second hit’
required to create homozygous mutant cells. This approach
could be applied to a variety of cell-based phenotypes, and
the gene-trap ES cell lines can be used for the production of
mutant mice for whole-animal studies. 
Neal Copeland (National Cancer Institute, Maryland, USA)
addressed the ambitious task of generating and navigating
the mouse cancer genome map. He articulated some of the
difficulties encountered in this endeavor: the sheer number
of loci of both major and minor effects, the difficulty of rec-
ognizing a cancer gene from its sequence, and the potential
for cooperative mutations in multiple genes. The predomi-
nant strategy for identifying cancer genes that is being used
in his and Nancy Jenkins’ laboratory (at the National Cancer
Institute, Maryland, USA) is to overexpress or inactivate
genes using retroviral insertion vectors. If a cancer gene is
mutated, a clonally derived tumor will be propagated. The
mouse genome sequence facilitates the rapid genomic posi-
tioning of the insertion sites and provides a preliminary
cancer genome map which, when combined with other
groups’ data, contains more than 235 candidate cancer
genes. Copeland then reviewed a recent gene-therapy trial in
France that used an IL2RG-containing retrovirus and suc-
ceeded in treating patients with X-linked severe combined
immunodeficiency (SCID), but two of the ten individuals
treated developed acute T-cell leukemia. Both tumors con-
tained retrovirus insertions in the 5 end of the LMO2 gene,
a recognized human T-cell proto-oncogene. Both the IL2RG
and LMO2 loci were hit in Copeland and Jenkins’ studies,
leading them to suggest that IL2RG is a proto-oncogene andthe prevalence of leukemia in this particular SCID trial is due to
the synergy between IL2RG and LMO2: the overexpression of
IL2RG from the retrovirus provides the first hit and the
second hit is the insertion of the retrovirus in a cooperating
gene such as LMO2. The cancer map generated from their
mouse experiments above will help predict such interactions
in the future, thereby reducing the risks associated with
gene-therapy trials. 
The forward progress of forward genetics
The power and feasibility of phenotype-driven screens using
the ‘supermutagen’ N-ethyl-N-nitrosourea (ENU) were
showcased by Steve Brown (MRC Mammalian Genetics Unit
and UK Mouse Genome Centre, Harwell, UK) and David
Beier (Brigham and Women’s Hospital, Harvard Medical
School, Boston, USA). Brown outlined the ongoing, substan-
tial mutagenesis program at Harwell, part of which has been
published. He and his colleagues have screened 35,000 mice
for dominant mutations, with an emphasis on sensory and
neurological defects, and his review of their current figures
is quite encouraging. Of the 1,500 abnormal phenotypes
identified by the screen, 376 mutants were subjected to
inheritance testing, 85 have been genetically mapped and 20
loci have been cloned. Brown concluded that at least half of
the mutants display novel phenotypes and thus provide
novel functional information. Furthermore, some mutants
have assigned new phenotypes to previously mutated genes,
emphasizing the unexpected information that can be
obtained by examining multiple alleles. Many mutants iden-
tified by Brown’s group affect auditory and vestibular func-
tions, and hold promise as models for human deafness
disorders. In particular, he detailed two mutants, Jeff and
Junbo, which have middle ear defects and model the human
inflammatory disease otitis media with effusion. The cloning
of  Jeff revealed a gene with no recognizable sequence
motifs, which is expressed in the middle ear epithelium. In
contrast, the Junbo mutation is a missense allele of Evi1, a
gene that had previously been annotated as a proto-onco-
gene and shown by gene targeting to be required for embry-
onic development.
A more humble, but no less productive, ENU mutagenesis
screen was described by Beier. Previously, his lab undertook
a three-generation recessive screen to identify organogenesis
mutants. The breeding scheme and phenotyping strategy for
this screen facilitated the simultaneous production, identifi-
cation and mapping of mutants with robust phenotypes,
which were the subject of his talk. A broad spectrum of phe-
notypes was uncovered and their primary characterization
suggests they represent several new mouse models for
human congenital diseases. One mutant strain with cleft-
palate defects contains a mutation in Prdm16, a zinc-finger-
encoding gene related to Evi1 but with no previous
functional data attributed to it. Another mutant, little lung,
exhibits phenotypes similar to a congenital diaphragmatic
defect in humans; the molecular lesion is a novel splicing-
defect allele of the Fog2 gene. Previous studies of Fog2 in
the mouse revealed an essential role for this gene during
heart development, which precluded the study of late devel-
opmental stages. The analysis of this hypomorphic Fog2
allele resulted in a similar take-home message to the Junbo
story - that such phenotype-driven forward genetic screens
can reveal phenotypes and novel alleles that complement
sequence-based approaches.
Building big pictures from small effects
The subject of complex quantitative traits was broached by
Jonathan Flint (Wellcome Trust Centre for Human Genetics,
Oxford, UK). His talk reminded us that most complex traits
are affected by many ‘loci of small effects’ (each accounting
for 5% or less of the phenotype). Flint pointed to the utility of
the mouse for identifying chromosomal regions containing
loci of small effects, but noted that gene identification has so
far been successful only for loci of large effects. The critical
reagent in his studies is the outbred HS mouse stock, which
was founded from eight different inbred mouse strains, and
has a high density of linkage disequilibrium and thus a
variety of haplotypes. Flint and co-workers used this strain in
earlier work to detect and finely map several behavioral traits
that model anxiety. Even though the genomic region defined
for one of their anxiety loci was ‘small’ by positional cloning
standards, the number of potential causative polymorphisms
numbered in the thousands. Flint discussed a comparative
method involving the HS parental strains which excluded a
large fraction of the putative candidates. Calculations of the
statistical power of these methods concluded his talk and
indicated that 2,000 HS mice would be sufficient to detect all
quantitative trait loci (QTLs) that have a minimum of 5%
phenotypic effect. The group’s current goal is to phenotype
and genotype 1,000 HS mice by the end of this year.
Joe Nadeau (Case Western Reserve University, Cleveland,
USA) also takes advantage of natural variation in mouse
strains, but his goal is to integrate complex systems with the
study of health and disease. Nadeau’s earlier work compared
two inbred strains, A/J and C57BL/6J (B6), across a variety
of physiological parameters with an emphasis on cardiovas-
cular properties. Even though both strains have a compara-
ble blood-flow output, there were numerous cardiovascular
phenotypes that differed between the two and must there-
fore have different genetic causes. With the help of AXB and
BXA recombinant inbred strains, which are derived from A/J
and B6 strains, his group was able to separate many cardio-
vascular properties genetically, to define relations between
the cardiovascular traits computationally, and to model a
functional network. This network was used to account for the
phenotypic changes in mice exhibiting pathological cardio-
vascular phenotypes due to single gene mutations. Nadeau
then turned to studies focused on folate-homocysteine
metabolism, noting that folic acid supplementation during
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and cardiovascular defects. The A/J and B6 inbred strains
were fed a folate-deficient diet followed by a replenishment
phase. A temporal analysis of folate and homocysteine levels
together with gene-expression profiling revealed that the
two inbred strains respond quite differently to this type of
environmental stress: unlike A/J mice, B6 inbred mice fail to
reestablish their original folate and homocysteine levels, and
their gene-expression status. Nadeau suggested that,
because of its environmental history, the B6 strain might
now be much more susceptible to a future disruption in the
folate-homocysteine metabolic pathway. The small, yet sig-
nificant, genetic variants in these two ‘wild-type’ strains are
assuredly similar to the gene-environment phenomena char-
acteristic of complex human diseases and should, therefore,
provide useful further insights.
Traditional techniques
What about the traditional method of studying a few
mutants at a time and focusing on them? Such approaches
are still vital and thriving, as demonstrated by two speakers
at the meeting. Rudi Balling (German Research Center for
Biotechnology, Braunschweig, Germany) broadened the dis-
cussion to include the interaction between the genomes of
the host and its pathogens, and touched on some points vali-
dating the mouse for the study of infectious diseases. His
group is subjecting a small collection of the immunological
mutants identified in the large German ENU mutagenesis
program to a battery of secondary screens for susceptibility
to different bacterial infections. Robin Lovell-Badge
(National Institute for Medical Research, London, UK) com-
pared and contrasted embryonic and adult stem cell popula-
tions and the unique environments they encounter. His
group has been studying a handful of developmentally regu-
lated Sox genes (Sox1, Sox2 and Sox3), which encode HMG-
box transcription factors. Previous analysis of the
Sox2-targeted mutant defined a function for the gene in the
stem-cell populations of the pre-implantation embryo. He
presented a variety of data using neurospheres - an in vitro
model system for studying neural stem cell development -
and cell transplantations, which together with previous data
indicate that Sox2 functions in both embryonic and adult
neural stem cells. The Sox2 gene, therefore, provides a useful
foothold for studying neural stem cell biology. Lovell-Badge
also emphasized that a stem cell’s ‘history’ influences its fate
and potential more than its environment does. 
Although most speakers emphasized methods of the post-
genomic era, the meeting included a delightful talk from
Mary Lyon who described some personal reminiscences with
respect to her more than 50 years in the mouse genetics
community. Lyon is probably most recognized for her
X-chromosome inactivation hypothesis, and at the conclu-
sion of her talk she was awarded the Mendel Medal for her
major contributions to the field of mouse genetics. While we
are now far removed from the tedious days of Lyon’s early
years when mapping was done with linkage testing stocks, it
was apparent from this meeting that much of the rich history
of mouse genetic resources, and enthusiasm continues in
this post-genomic age of mouse genetics. 
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